Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  valspodar
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-21 of 21 for your search:
Start Over
Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065178, E-1A95, CAN-NCIC-MY8, CLB-E1A95, EORTC-E1A95/06971, SWOG-E1A95, CAN-NCIC-J1A95, CLB-9596, SWOG-S1A95, MY8, NCT00002878
Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 60 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02793, CALGB-9720, U10CA031946, CLB-9720, NCT00003190
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 15 to 59
Sponsor: NCI
Protocol IDs: NCI-2012-02824, CALGB-19808, U10CA031946, NCT00006363
Phase I/II Study of DHAD/VP-16 with PSC 833 as Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (Summary Last Modified 12/95)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 17 and over
Sponsor:
Protocol IDs: MDA-DM-94052, NCI-V95-0604
Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 15 to 59
Sponsor: NCI
Protocol IDs: CDR0000065333, U10CA031946, CLB-9621, CALGB-9621, NCT00002925
Phase I/II Study of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer (Summary Last Modified 02/2001)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-97-C-0074C, NCI-T96-0011, T96-0011
Phase II Study of Paclitaxel and Oral PSC 833 (a Nonimmunosuppressive Cyclosporine Analogue) in Persistent or Recurrent Ovarian Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: GOG-126E
Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065011, E-1195, NCT00002826
Phase II Study of PSC 833 plus Doxorubicin in Metastatic Breast Cancer Refractory to Anthracyclines or Anthracenediones (Summary Last Modified 06/1999)
Phase: Phase II
Type: Treatment
Status: Closed
Age: over 18
Sponsor: NCI
Protocol IDs: MAYO-943001, NCI-V96-1077
Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CDR0000065380, U01CA063265, CHNMC-96002, NCI-H97-1137, NCT00002937
S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 56 and over
Sponsor: NCI, Other
Protocol IDs: S9918, U10CA032102, SWOG-S9918, NCT00004217
Phase I Study of Paclitaxel with PSC 833 for Advanced Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: NCI
Protocol IDs: NCI-94-C-0119I, NCI-MB-330, NCI-T93-0123N, T93-0123
Phase I Study of TAX/PSC 833 for Refractory Solid Tumors (Summary Last Modified 02/00)
Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: WU-95-0718, NCI-T93-0034O, T93-0034
Phase I Study of Mitoxantrone/Etoposide/PSC 833 in Patients 56 Years of Age and Over with Previously Untreated Acute Myeloid Leukemia (Summary Last Modified 11/98)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 56 and over
Sponsor: NCI
Protocol IDs: SWOG-S9617, SWOG-9617, S9617
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Under 22 at diagnosis
Sponsor: NCI
Protocol IDs: NCI-2012-01835, POG-9423, CCG-P9423, CDR0000065285, P9423, NCT00002912
Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066062, WU-106, NCI-T97-0073, T97-0073, NCT00003207
Phase I Study of Vinblastine with the P-Glycoprotein Antagonist PSC 833 for Metastatic Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: NCI
Protocol IDs: NCI-92-C-0268K, NCI-T92-0100N, NCI-MB-288
Start Over